Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

TRUST : BINTRAFUSP ALFA AND DOXORUBICIN HYDROCHLORIDE IN TREATING PATIENTS WITH ADVANCED SARCOMA Ended

2023-509497-30-00 Adult patients with locally advanced/unresectable and/o 4 2022-02-21
A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended

2023-503640-14-00 Newly diagnosed Philadelphia-negative B-cell precursor 5 2022-02-17
Assessment of tolerance and effectiveness of total body irradiation and cladribine before allogeneic hematopoietic cell transplantation in p… Ended

2024-517477-24-00 Acute myeloid leukemia, myelodysplastic syndromes 4 2022-02-17
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I… Ended

2024-515617-18-00 Advanced clear cell renal cell carcinoma (ccRCC), non-c 1 2022-02-14
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and pr… Ended

2024-512487-61-00 Unresectable pancreatic cancer 5 2022-02-10
Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended

2024-518304-53-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-02-02
Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended

2024-510655-36-00 Advanced Malignancies Associated with EphA2 Expression 7 2022-02-01
Lutetium after second-line hormonal treatment [PBP-301] [SPLASH] Ended

2024-515604-39-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2022-01-28
PERCEPTION Ended

2023-508155-40-00 recurrent platin sensitive low-grade serous ovarian-, f 4 2022-01-25
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic head and neck cancer patients Ended

2024-514919-10-00 Locally advanced head and neck squamous cell carcinoma 6 2022-01-24
FIRST-IN-HUMAN STUDY OF IPH5301 TREATMENT ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS Ended

2023-504605-36-00 Dose escalation cohort: advanced and/or metastatic canc 1 2022-01-21
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (… Ended

2024-515902-15-00 Male and female adult patients with locally advanced or 4 2022-01-18
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 "Inoperable or Metastatic Hormone Receptor-Positive, HE 5 2022-01-18
ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoa… Ended

2024-513297-21-00 Locally advanced rectal cancer 4 2022-01-14
Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten… Ended

2023-505514-15-00 Small-cell lung cancer, extensive stage 5 2022-01-11
A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 in subjects with Advanced Systemic Mastocy… Ended

2024-511407-42-00 Advanced Systemic Mastocytosis 4 2022-01-10
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 B-cell non-Hodgkin lymphoma (NHL) 9 2021-12-27
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma Ended

2023-503620-60-00 multiple myeloma 3 2021-12-22
A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended

2024-511599-33-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-12-22
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC). Ended

2024-511837-37-00 Relapsed/Refractory Small Cell Lung Cancer 4 2021-12-21
DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car… Ended

2023-505210-18-00 Early stage HER2-positive breast cancer (T stage >= T3, 5 2021-12-17
A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S… Ended

2023-503674-20-00 Unresectable, locally advanced, or metastatic Non-Small 5 2021-12-17
This is a multicenter, randomized, Phase 3 study with vimseltinib or placebo in patients with Tenosynovial Giant Cell Tumor, consisting of 2… Ended

2024-513624-42-00 Tenosynovial Giant Cell Tumor 5 2021-12-16